Mathys & Squire will be offering a webinar entitled "Antibodies and non-obviousness at the EPO" on July 7, 2020 from 6:00 to 7:00 pm (GMT Summer Time). Martin MacLean and Hazel Ford of Mathys & Squire LLP will discuss the arguments that are most likely to be effective when addressing inventive step objections at the European Patent Office in the antibody field, including the effects or advantages that might be relied upon, and the types of evidence that might be deployed to support an antibody claim. They will also discuss the breadth of claims that might be obtained in different circumstances based on current EPO practice, and will consider when questions of lack of enablement are most likely to arise in an antibody case.
While there is no cost to participate in the program, those interested in attending the webinar can register here.
Comments